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Abstract
Background and Aims: Liver stiffness measurement (LSM) using transient elastography (FibroscanH) can identify individuals
with potential underlying liver disease. We evaluated the prevalence of abnormal LSM values as assessed using LSM and its
predictors in HIV-infected asymptomatic patients receiving combined antiretroviral treatment (cART) without HBV/HCV
coinfection.
Methods: We prospectively recruited 93 patients who had consistently been undergoing cART for more than 12 months at
Severance Hospital in Seoul, Republic of Korea, from June to December 2010. LSM values .5.3 kPa were defined as
abnormal.
Results: Thirty-nine (41.9%) had abnormal LSM values. On multivariate correlation analysis, the cumulative duration of
boosted and unboosted protease inhibitors (PIs) were the independent factors which showed a negative and positive
correlation to LSM values, respectively (b= –0.234, P= 0.023 and b= 0.430, P,0.001). In multivariate logistic regression
analysis, the cumulative exposure duration of boosted-PIs and c-glutamyltranspeptidase levels were selected as the
independent predictors which showed a negative and positive correlation with abnormal LSM values, respectively (odds
ratio [OR], 0.941; 95% confidence interval [CI], 0.889–0.997; P= 0.039 and OR, 1.032; 95% CI, 1.004–1.060; P= 0.023).
Conclusion: The high percentage of HIV-infected asymptomatic patients receiving cART without HBV/HCV coinfection had
abnormal LSM values. The cumulative exposure duration of boosted-PIs and c-GT level were independent predictors which
showed a negative and positive correlation with abnormal LSM values, respectively.
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Introduction
Because the life expectancy in HIV-infected individuals has
increased continuously since the introduction of effective com-
bined antiretroviral treatment (cART), non-AIDS defined com-
plications, such as cardiovascular disease, osteoporosis, non-AIDS
defining malignancies, renal disease, and chronic liver disease, are
now being considered more important causes of morbidity and
mortality than opportunistic infections (OIs). [1–7].
Notably, chronic liver disease has become an important cause of
morbidity and mortality in HIV-infected individuals. [2,7]
Although hepatitis B (HBV) or C virus (HCV) coinfection is the
main cause of chronic liver damage, alcohol consumption, drugs
(especially antiretroviral drugs), and non-alcoholic steatohepatitis
can be other causes. [7] Among these, due to long-term use of
cART, many HIV-infected patients are facing potential sequelae
of cART-induced hepatotoxicity, such as the development of liver
fibrosis. [7].
If elevation of liver enzymes is identified during cART at visits
of regular follow-up, physicians can modify their treatment
strategies. However, these adverse reactions by cART are often
subject to physician indifference because 50% of patients are
asymptomatic when liver enzymes are raised. [8] Furthermore,
HIV-infected patients, even those with no elevation of liver
enzymes, are also vulnerable to asymptomatic liver damage. Thus,
early detection of asymptomatic liver damage showing normal
liver enzyme in HIV-infected patients without HBV or HCV
coinfection receiving long-term cART is of paramount importance
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to preventing the silent progression of liver fibrosis, resulting in
advanced fibrosis or cirrhosis.
Recently, noninvasive liver stiffness measurement (LSM) using
transient elastography (FibroscanH) has been performed to
evaluate the severity of liver fibrosis and to screen the general
population for subjects at risks of having underlying liver disease
with high reproducibility. [9,10] Using LSM, one previous study
reported prevalence and risk factors for abnormal LSM values in
HIV-infected patients without viral hepatitis coinfection. [11]
However, the cutoff LSM value used in that study to define HIV-
infected patients with abnormal LSM values was adopted from the
LSM value for predicting significant fibrosis in HIV/HCV co-
infected patients who may already have had a fibrotic background
liver due to chronic HCV infection, leading to the cutoff LSM
values being elevated. [11] Thus, the overestimated cutoff LSM
values in the previous study may have underestimated the
prevalence of HIV-infected patients with abnormal LSM values.
In this study, to overcome the confounding effect of coinfection
with hepatitis virus, we adopted cutoff LSM values derived from
healthy individuals [12] and investigated the prevalence of
abnormal LSM values and its predictors in HIV mono-infected
asymptomatic patients.
Materials and Methods
Study Participants and Design
We prospectively enrolled 125 HIV-infected patients to perform
a prospective cross-sectional observational study at Severance
Hospital, a 2,000-bed, university-affiliated tertiary teaching
hospital in Seoul, Republic of Korea from June to December
2010.
To clarify the effects of long-term cART on asymptomatic liver
damage, reflected by abnormal LSM values, we included only
HIV-infected asymptomatic patients with normal alanine amino-
transferase (ALT) and total bilirubin who had continuously
received cART more than 12 months and visited regularly at 3-
month intervals. We further excluded patients who filled the
following exclusion criteria; (1) LSM failure (no valid shots) or
unreliable LSM (n= 5, 4.0%) (2) chronic HBV/HCV coinfection
or acute hepatitis A virus infection, (3) any active OIs or AIDS-
defining illnesses including malignancy while undergoing current
treatment, (4) underlying illness or past treatment history of
chronic liver or renal or lung disease defined according to the
International Classification of Disease, 10th Revision, [13] (5)
ultrasonographic evidences of structural liver abnormality, (6)
alcohol consumption in excess of 40 g/day for more than 5 years,
(7) any medication besides cART with potential hepatotoxicity
within 6 months of enrollment (lipid-lowering agents and liver pills
or folk medicine including herb et al), (8) interruption of cART for
any reasons including adverse reactions and poor adherence, (9)
patients referred to our hospital after HIV diagnosis, and (10)
right-sided heart failure. Taking into account these exclusion
criteria, a total of 93 patients were finally recruited (Figure 1).
This study was approved by the local Institutional Review
Board of the Clinical Research Institute of Severance Hospital. All
participants gave informed consent for their participation in this
study.
Laboratory Tests and Data Collections
In addition to demographic data, CD4+ T lymphocyte count,
plasma HIV-RNA viral load (VL), liver function tests, including
aspartate aminotransferase (AST), ALT, alkaline phosphatase
Figure 1. Recruitment flow of study participants for this study. NOTE. LSM, liver stiffness measurement; HBV, hepatitis B virus; HCV, hepatitis
C virus; HAV, hepatitis A virus; OI, opportunistic infection; AIDS, acquired immunodeficiency syndrome; cART, combined antiretroviral treatment.
doi:10.1371/journal.pone.0052720.g001
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(ALP), total bilirubin, c-glutamyl transferase (c-GT), prothrombin
time (PT), and platelet count were collected on the same day as
LSM examination. The upper limit of normal (ULN) was set as
40 IU/L for ALT and 1.2 mg/dL for total bilirubin. Thus,
patients with abnormal liver-related laboratory findings related to
potential underlying liver disease, defined as ALT .40 IU/L and
total bilirubin .1.2 mg/dL, were not enrolled in this study [12].
Several covariates have been collected by the retrospective
review of the electrical medical record. These included mode of
transmission, time since HIV infection diagnosis, history of AIDS
defining illness and Centers for Disease Control and Prevention
(CDC) category B illness, [14] the nadir CD4+ T lymphocyte
count, plasma highest VL value after HIV diagnosis and cART
regimens. We reviewed cART in detail, including the total
duration of treatment, whether or not antiretroviral drugs were
changed, current regimens upon LSM examination, and cumu-
lative exposure duration to each antiretroviral drug after cART
initiation.
Liver Stiffness Measurement and Ultrasonographic
Evaluation
LSM using FibroScanH was performed by a single physician
blinded to clinical and biochemical data according to the
instructions provided by the manufacturer. Details of the technical
background and examination procedure have been previously
described. [9,15] The success rate was calculated as the number of
valid measurements divided by the total number of measurements.
The results were expressed as kilopascals (kPa). Interquartile range
(IQR) was defined as an index of intrinsic variability of LSM
corresponding to the interval of LSM results containing 50% of
the valid measurements between the 25th and 75th percentiles.
The median value was considered representative of the elastic
modulus of the liver. Only procedures with at least 10 valid
measurements, a success rate of at least 60% and an IQR to
median value ratio ,30% were considered reliable.
Ultrasonographic evaluation was also performed by a single
physician blinded to the clinical and biochemical data to exclude
any structural or morphological liver abnormalities that could
influence LSM values.
Definition of Abnormal LSM Values
Because HIV mono-infected asymptomatic patients were
recruited, we needed cutoff LSM values derived from a healthy
population without background chronic liver disease that could
raise LSM values and subsequently underestimate the prevalence
of patients with abnormal LSM values. Although several previous
studies proposed their own normal ranges for LSM values, [16] we
adopted 5.3 kPa, which was derived from Korean healthy living-
related liver and kidney donors, as the cutoff LSM value for
Table 1. Baseline characteristics and antiretroviral drug regimens of study participants upon LSM examination (n = 93).
Variables Values
Age, years 42.9610.3
Male gender 88 (94.6)
Mode of transmission
Heterosexual/homosexual/not clarified 40 (43.0)/24 (25.8)/29 (31.2)
Change of antiretroviral druga 47 (50.5)
Time since HIV infection diagnosis, months 78.9666.9
Total cART duration, months 50.4637.8
Past history of AIDS defining illness and CDC category B illness 48 (51.6)
CD4+ T lymphocyte counts, cells/mm3 502.96245.5
Plasma HIV-RNA viral load (,20 copies/mL) 76 (81.7)
LSM value, kPa 4.9 (4.3–5.9)
Body mass index, kg/m2 22.463.0
Liver function tests
Alanine aminotransferase, IU/L 19.465.7
Alkaline phosphatase, IU/L 62.2622.8
Total bilirubin, mg/dL 0.7160.16
c-glutamyltranspeptidase, IU/L 49.8647.3
Prothrombin time, INR 0.9260.06
Platelet count, X 103/mm3 260.96229.1
Antiretroviral drugs at LSM examination
NRTIs
Zidovudine/didanosine/stavudine/abacavir 44 (47.3)/28 (30.1)/4 (4.3)/22 (23.7)
NNRTI (all efavirenz) 39 (41.9)
PIs 53 (57.0)
NOTE. Data are expressed as mean6 SD, number (percent), or median (interquartile range). LSM, liver stiffness measurement; cART, combined antiretroviral treatment;
AIDS, Adult immunodeficiency syndrome; CDC, Centers for Disease Control and Prevention; kPa, kilopascal; INR, international normalized ratio; NRTIs, nucleoside
analogue reverse transcriptase inhibitors; NNRTIs, non-nucleoside analogue reverse transcriptase inhibitors; PIs, protease inhibitors. aA change to co-formulated drugs
with the same components was not considered to be a change in antiretroviral drugs.
doi:10.1371/journal.pone.0052720.t001
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stratifying our study population into HIV-infected asymptomatic
patients with normal and abnormal LSM values.
Statistical Analyses
The data were expressed as the mean6 standard deviation (SD)
for continuous variables with normal distribution or median (IQR)
without normal distribution and as the number (percent) for all
categorical variables. To evaluate the correlation between various
covariates and LSM values, we performed univariate Pearson’s or
non-parametric (Spearman’s r) correlation and multivariate linear
regression analysis as the standardized regression coefficients with
variables with P-value of less than 0.1 upon univariate correlation
analysis.
The Student’s independent T-test or Mann-Whitney U-test
were used to compare the mean values of continuous variables
with normal or skewed distribution between the groups with
normal and abnormal LSM values. To analyze the differences in
nominal variables between the two groups, we performed a chi-
square test or Fisher’s exact test. Finally, multivariate logistic
regression analysis was performed to identify the associated clinical
factors with abnormal LSM values. In this final model, we
included several independent variables with P-values of less than
0.1 upon univariate analysis between the two groups, respectively.
The optimal cutoff values of the independent variables were
selected to maximize the sum of sensitivity and specificity derived
from the receiver operating characteristic (ROC) curves and the
area under ROC (AUC) analysis.
All P-values were two-tailed, and P,0.05 was considered to be
statistically significant. We used SPSS 18.0 software (SPSS Inc.,
Chicago, IL, USA) to perform all statistical analysis.
Results
The Baseline Characteristics and Antiretroviral Drug
Regimens of Study Participants upon LSM Examination
The baseline characteristics and antiretroviral drug regimens of
the study participants upon LSM examination are summarized in
Table 1. The minimum and maximum LSM values of total
patients were 3.3 and 10.0 kPa (Figure 2). The mean value of
nadir CD4+ T lymphocyte counts was 150 cells/mm3 and the
highest plasma HIV-RNA VL was log 5.0 copies/mL.
The mean value of cumulative exposure duration of each
nucleoside analogue reverse transcriptase inhibitor (NRTI) drug
until LSM examination was zidovudine (AZT) 23.2, didanosine
(ddI) 14.0, stavudine (d4T) 7.6, and abacavir (ABC) 8.4 months,
respectively. In addition, the mean values of cumulative exposure
duration of efavirenz (EFV) and low-dose ritonavir (RTV) boosted
lopinavir (LPV/r) were 19.3 and 18.9 months, respectively.
Figure 2. Distribution of LSM values among all study
participants. NOTE. The dotted line indicates the cutoff value for
abnormal LSM (5.3 kPa). LSM, liver stiffness measurement; kPa,
kilopascal.
doi:10.1371/journal.pone.0052720.g002
Table 2. Correlation between LSM values and other variables.
Independent variables Univariate
a Multivariate
r (P-value) b (P-value)
Age, years 0.002 (0.984) –
Time since HIV infection diagnosis,
months
20.086 (0.412) –
Total duration of cART, months 20.011 (0.917) –
CD4+ T lymphocyte counts, cells/mm3
At LSM examination 20.186 (0.074) 20.755 (0.452)
Nadir 20.039 (0.714) –
Plasma HIV-RNA viral load, copies/mL
At LSM examination 20.017 (0.868) –
Log10(highest value after the HIV
diagnosis)
0.090 (0.402) –
Body mass index, kg/m2 20.025 (0.819) –
Alanine aminotransferase (IU/L) 0.120 (0.251) –
Alkaline phosphatase (IU/L) 0.143 (0.170) –
Total bilirubin (mg/dL) 20.037 (0.725) –
c-glutamyltranspeptidase (IU/L) 0.119 (0.525) –
Prothrombin time, INR 0.181 (0.241) –
Platelet count, X 103/mm3 20.112 (0.287) –
Cumulative exposure duration of antiretroviral drugs, monthsb
NRTIs
Zidovudine (n = 68) 0.127 (0.301) _
Stavudine (n = 25) 20.247 (0.234)c _
Didanosine (n = 39) 0.117 (0.477) _
Abacavir (n = 23) 20.059 (0.788)c _
NNRTIs (n = 54) 0.230 (0.095) _
PIs (n = 58) 0.043 (0.747)
Boosted (n = 50) 20.241(0.092) 20.234 (0.023)
Unboosted (n = 31) 0.401 (0.025) 0.430 (,0.001)
NOTE. aPearson’s correlation coefficient, bCorrelation analyses in only patients
who has ever been received each antiretroviral drug, cSpearman’s r. LSM, liver
stiffness measurement; cART, combined antiretroviral treatment; INR,
international normalized ratio; NRTIs, nucleoside analogue reverse transcriptase
inhibitors; NNRTIs, non-nucleoside analogue reverse transcriptase inhibitors; PIs,
protease inhibitors.
doi:10.1371/journal.pone.0052720.t002
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Correlation between LSM Values and Other Variables
On univariate analysis, the cumulative exposure duration of
unboosted PIs had a significant positive correlation with LSM
value (r=0.401, P= 0.025), whereas CD4+ T lymphocyte counts
and boosted PIs showed borderline correlations with LSM values,
respectively (r=–0.186, P= 0.074 and r=–0.241, P= 0.092).
However, on subsequent multivariate linear regression analysis,
the cumulative exposure duration of boosted and unboosted PIs
were selected as independent factors that had a significant negative
and positive correlation with LSM value, respectively (b=–0.234,
P= 0.023 and b= 0430, P,0.001) (Table 2).
Comparison between Patients with Normal and
Abnormal LSM Values
Thirty nine subjects (41.9% of the study population) showed
abnormal LSM values (Table 3), and these patients had a
significantly shorter time period from HIV infection diagnosis than
those with normal LSM values (P=0.049). Although statistical
significance was borderline, patients with abnormal LSM values
had higher nadir CD4+ T lymphocyte counts (P=0.082), lower
total bilirubin (P=0.050), higher c-GT (P=0.086), lower PT
(P=0.099), and absence of exposed history of boosted-PIs
(P=0.094) (same order with table) than those with normal LSM
values upon univariate analysis (Table 3). Any significant
differences were not revealed in comparisons of current antiret-
roviral regimens at the LSM examination between patients with
normal and abnormal LSM values (data not shown). When the
cumulative exposure duration of each antiretroviral drug was
compared between patients with normal and abnormal LSM
values, only the exposure duration of boosted PI was significantly
different (mean 26.5 vs. 14.0 months; P=0.021).
Independent Predictors of Abnormal LSM Values
On multivariate logistic regression analysis, the cumulative
exposure duration of boosted PIs and c-GT level were selected as
independent predictors which showed a negative and positive
correlation with abnormal LSM values, respectively (odds ratio
[OR], 0.941; 95% confidence interval [CI], 0.889–0.997;
Table 3. Comparisons of baseline characteristics and cumulative exposure durations of antiretroviral drugs between patients with
normal and abnormal LSM values.
Variables
Patients with normal LSM
values (n =54, 58.1%)
Patients with abnormal LSM
values (n =39, 41.9%) P-value
Age, years 42.169.8 43.9611.1 0.421a
Gender, male 52 (96.3) 36 (92.3) 0.646b
Time period since HIV infection diagnosis, months 90.5680.9 62.9635.5 0.049a
Total duration of cART, months 62.1636.7 50.5630.3 0.108a
CD4+ T lymphocyte counts, cells/mm3
At LSM examination 528.06239.7 468.06252.3 0.247a
Nadir 132.7699.3 173.66120.6 0.082a
Plasma HIV-RNA viral load, copies/mL
Undetectable rangee at LSM examination, yes, n (%) 46 (85.2) 30 (76.9) 0.416c
Log10(highest value after the HIV diagnosis) 5.061.0 5.060.8 0.832
a
Body mass index, kg/m2 22.563.0 22.462.9 0.860a
Alanine aminotransferase, IU/L 22.9612.3 26.6617.4 0.238a
Alkaline phosphatase, mg/dL 61.8626.3 62.7617.1 0.863a
Total bilirubin, mg/dL 1.061.0 0.760.5 0.050a
c-glutamyltranspeptidase, IU/L 36.4629.5 74.2663.7 0.086a
Prothrombin time, INR 0.9360.06 0.9060.06 0.099a
Platelet count, X 103/mm3 2876294 225661 0.195a
Exposed history of antiretroviral drugs, yes, n (%)
NNRTIs 33 (61.1) 21 (53.8) 0.484c
PIs 36 (66.7) 22 (56.4) 0.314c
Boosted 33 (61.1) 17 (43.6) 0.094c
Unboosted 18 (33.3) 13 (33.3) 1.000c
NRTI backbone
Zidovudine 39 (72.2) 29 (74.4) 0.819c
Stavudine 17 (31.5) 8 (20.5) 0.239c
Didanosine 22 (40.7) 17 (43.6) 0.784c
Abacavir 16 (29.6) 7 (17.9) 0.198c
NOTE. Data are expressed as mean 6 SD or number (percent). aIndependent sample two T-test, bFisher’s exact test, cChi-square test, and dMann-Whitney U-test were
used. eThe undetectable range was defined as fewer than 20 copies/mL. LSM, liver stiffness measurement; cART, combined antiretroviral treatment; INR, international
normalized ratio; NNRTI, non-nucleoside analogue reverse transcriptase inhibitor; cART, combined antiretroviral treatment; PI, protease inhibitors; NRTI, nucleoside
analogue reverse transcriptase inhibitor.
doi:10.1371/journal.pone.0052720.t003
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P=0.039 and OR, 1.032; 95% CI, 1.004–1.060; P=0.023)
(Table 4). The significant correlation between the cumulative
exposure duration of boosted PIs and LSM values is described in
Figure 3.
Optimal Cutoff Values for Independent Predictors of
Abnormal LSM Values
The optimal cutoff values of the cumulative exposure duration
for boosted-PIs and c-GT were calculated as 33 months
(P=0.041; area under the ROC curve [AUROC]= 0.619; 95%
CI, 0.506–0.733; sensitivity, 38.9%; specificity, 87.2%; PPV,
80.8%, and negative predictive value [NPV], 50.7%) and 32 IU/L
(P=0.010; AUROC=0.782; 95% CI, 0.606–0.958; sensitivity,
42.6%; specificity, 38.5%; PPV, 48.9%, and NPV, 32.6%).
Abnormal LSM values were observed in 34 of 67 (50.7%)
patients with cumulative exposure duration of boosted-PIs of ,33
months and 5 of 26 (19.2%) patients with cumulative exposure
duration of boosted-PIs of $33 months (OR, 0.61; 95% CI, 0.45–
0.83; P=0.006) (Figure 4a). Similarly, abnormal LSM values were
observed in 15 of 46 (32.6%) patients with c-GT level ,32 IU/L
and 24 of 47 (51.1%) patients with c-GT level $32 IU/L (OR,
2.49; 95% CI, 1.30–4.75; P=0.001) (Figure 4b).
Discussion
Recently, there has been increasing concern regarding cART-
induced hepatotoxicity. [7] cART may cause liver damage via a
variety of mechanisms such as mitochondrial toxicity, drug
hypersensitivity reactions, idiosyncratic hepatotoxicity, immune
reconstitution syndrome and hepatic steatosis et al. [17].
If HIV-infected patients have no subjective symptoms and show
normal ALT range and total bilirubin levels similar to our study
population, potential liver damage seems to be difficult to
recognize in clinical practice. However, it has been revealed that
a significant proportion of HIV-infected patients receiving cART
without HBV/HCV coinfection showed abnormal LSM values,
indicating potential asymptomatic liver damage. To our knowl-
edge, this is the first cross-sectional study to evaluate the
prevalence of abnormal LSM values in HIV-infected asymptom-
atic patients receiving long-term cART without HBV/HCV co-
infection, assessed using cutoff LSM values derived from healthy
population.
Although several studies have concluded that HIV-infected
patients with HBV or HCV coinfection have significantly more
advanced liver fibrosis than those without co-infection with the aid
of LSM, [18–20] the assessment of asymptomatic liver damage
using LSM in HIV mono-infected patients receiving long-term
cART has been rarely addressed. To date, one study evaluated the
prevalence and risk factors for abnormal LSM values without
Figure 3. Scatter plot showing the correlation between antiretroviral treatment and LSM value in patients who have been exposed
to boosted PIs (n =50) among study participants (b=20.234, P=0.023).
doi:10.1371/journal.pone.0052720.g003
Table 4. Multivariate logistic regression analysis to identify
the independent predictors of abnormal LSM values.
Independent variables OR 95% CI P-value
Cumulative exposure duration of boosted-PIs 0.941 0.889–0.9970.039
c-glutamyltranspeptidase, IU/L 1.032 1.004–1.0600.023
Included variables in this final model: Cumulative exposure duration of
boosted-PIs, c-glutamyltranspeptidase, total bilirubin, time period since HIV
infection diagnosis, and prothrombin time. LSM, liver stiffness measurement;
OR, odds ratio; CI, confidence interval; PIs, protease inhibitors.
doi:10.1371/journal.pone.0052720.t004
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coinfection using the cutoff LSM value of 7.2 kPa, concluding that
the prevalence of liver damage was 11.2% and that long-term
exposure to ddI is a major risk factor for abnormal LSM values.
[11] However, because 7.2 kPa might have been overestimated
due to underlying liver fibrosis caused by chronic HCV infection,
it might have reduced the prevalence of abnormal LSM values in
HIV mono-infected asymptomatic patients. Another recent study
by Stabinski et al. which used a cutoff value of 9.3 kPa for
diagnosing significant fibrosis, not for asymptomatic liver damage,
concluded that the burden of liver fibrosis among HIV-infected
rural Ugandans is high and that the prevalence of significant
fibrosis in HIV-infected individuals was significantly higher than
non-HIV-infected individuals (17% vs. 11%, P=0.008) [21].
However, patients with mild asymptomatic liver damage might
have been improperly stratified into the normal group.
Considering that early detection of asymptomatic liver damage
in HIV mono-infected patients receiving long-term cART and
subsequent modification of treatment strategies to prevent
additional liver damage is of paramount important and that
confounding liver damage by other viruses should be excluded
from the evaluation of HIV mono-infected patients, the LSM
cutoff value used to identify patients with abnormal LSM values in
previous studies does not seem optimal. Indeed, the prevalence of
patients with abnormal LSM values in our study (41.9%) using
relatively lower cutoff LSM values derived from a healthy
population was significantly higher than those of two previous
studies (11.2% and 11%). [11,21] These results might also support
the idea that the cutoff LSM values in previous studies might have
been biased due to the confounding effect of liver damage from the
hepatitis virus and the commitment to predict more than
significant fibrosis.
In this study, the cumulative exposure durations of boosted-PIs
and the c-GT level were selected as significant predictors which
showed a negative and positive correlation with LSM values,
respectively. The use of low-dose RTV (100 mg/day) showed the
protective effects for abnormal LSM values in our study. PIs have
been frequently associated with the development of various
metabolic complications. [22] These have been associated with
liver damage by non-alcoholic fatty liver disease. [23] Low-dose
RTV is a strong hepatic cytochrome P450 3A inhibitor that helps
boost the pharmacokinetics of PI drugs and seems to be well
tolerated. [24] Two previous studies reported that cART with
LPV/r showed a low incidence of hepatotoxicity. [25,26] The
inhibitory effects of low-dose RTV on the metabolism of PIs in the
liver might result in a protective role of boosted PIs on abnormal
LSM values. However, the precise mechanism for role of boosted
PIs on abnormal LSM values is unknown at present. Therefore,
future laboratory and clinical research is warranted to clarify this
result.
In addition, c-GT level was also identified as an independent
predictor of abnormal LSM values. Among various etiologies for
elevated c-GT, alcohol consumption can be suspected first,
although patients with heavy alcohol consumption were excluded
from our study. Thus, when isolated c-GT elevation was noted in
HIV-infected patients, detailed history-taking regarding alcohol
consumption and abstinence from alcohol should first be
attempted. The calculated optimal cutoff value of c-GT (32 IU/
L) was significantly lower than ULN of c-GT (54 IU/L) [12]
indicating that abnormal LSM values can be identified even in
subjects with normal c-GT level. However, because the usefulness
of elevated c-GT level is limited due to its lack of specificity in spite
of high sensitivity in detecting hepatobiliary disease, the clinical
implications of using c-GT to detect abnormal LSM values in
HIV-patients should be further investigated.
This study has the some limitations. First, liver biopsy was not
performed. Thus, we could not confirm that patients with normal
LSM values had histologically normal livers. We were thus unable
to exclude the potential presence of OIs in the liver such as
cytomegalovirus and herpes simplex virus, due to the absence of
biopsy data. However, liver biopsy in asymptomatic patients with
normal ALT and total bilirubin level is not ethical in clinical
practice and the risk of OIs could have been ignored due to the
high mean CD4+ T lymphocyte count of 503 cells/mm3 upon
LSM examination. Second, the majority of our study participants
were male. Because LSM values might differ between genders,
[27] larger scale studies including a sufficient number of female
HIV-infected patients should be conducted in the future. Third,
because this was a cross-sectional study, a long-term follow-up
Figure 4. Percentage of patients with abnormal LSM values according to cutoff values of the cumulative exposure duration of
boosted-PIs (a) and c-GT level (b).
doi:10.1371/journal.pone.0052720.g004
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longitudinal study should reveal whether we should modify
treatment strategy for patients showing abnormal LSM values to
improve treatment outcomes and whether treatment outcomes are
really poorer in HIV mono-infected patients with abnormal LSM
values than in those with normal LSM values.
In conclusion, we identified a high prevalence of abnormal
LSM values in HIV-infected asymptomatic patients receiving
cART without HBV/HCV coinfection. We also found that the
cumulative exposure of boosted-PIs and c-GT level were
independent predictors which showed a negative and positive
correlation with abnormal LSM values, respectively.
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